Response to Comments: MolDX: Melanoma Risk Stratification Molecular Testing

This document is a response-to-comments notice for MolDX DecisionDX-Melanoma LCD, renamed to "MolDX: Melanoma Risk Stratification Molecular Testing," with a notice period beginning 2020-11-05 and effective date 2020-12-21. The provided text contains only administrative information and comments summary metadata and does not include specific coverage, limitation, documentation, or frequency criteria; review of the referenced LCD (L38016 / DL38016) is required to extract operational coverage criteria.